A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
about
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseΜanagement of patients with hepatitis B and C before and after liver and kidney transplantationThrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease.Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV.Future treatment of patients with HCV cirrhosis.Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver diseaseSerum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host defenses.Noncoding RNA as therapeutic targets for hepatocellular carcinoma.Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?Treatment of patients with HCV related cirrhosis: many rewards with very few risks.Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugsIndividualized treatment strategies and predictors of virological response for chronic hepatitis C: a multicenter prospective study from China.Current and emerging antiviral treatments for hepatitis C infectionIMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.Addicts with chronic hepatitis C: difficult to reach, manage or treat?Direct-acting antiviral agents in patients with hepatitis C cirrhosis.Nutrition assessment and management in advanced liver disease.Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization.Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand.Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis.The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters.Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load.The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults.Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.Chronic ingestion of ethanol induces hepatocellular carcinoma in mice without additional hepatic insult.Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity.
P2860
Q26752433-F7167959-5A72-4065-9755-5E865A693F2EQ26864647-D298BC2C-89D7-4392-927A-06B38BF8C325Q33403528-43185407-155E-460A-B5D6-C364DFB168BCQ33406835-AD44BA6D-C7AF-4BA1-9C5B-619BEB192E05Q33410537-53A24B1E-DDEB-4C71-AC4F-BE838AC1A251Q33414281-BB08D15C-EFFE-4783-8810-BD6F138BFC17Q33430833-1C8438FE-5299-4EE0-A0E7-203ED72DFCCFQ34163411-F79BFB94-21E8-4E8D-9680-C74A3E6E6651Q34243993-11C6A8BD-C650-49FD-834A-6991182D97D8Q34467312-1CDA419F-892B-4464-B759-E1F604A3E3C8Q35105799-DEC57E24-535F-42F8-AEFB-3DF6C0C595A2Q35168268-365D1596-116E-48A2-AFAE-27E2B11003B1Q35531310-170E2352-4A44-4111-8BE1-06CD5CF64F15Q35592207-F66F3FE0-FC90-456A-A55F-42318AF5470AQ35790393-164A129B-60A8-4AEE-8846-0D3AC83A11B9Q36142732-CDFA0B10-5FBC-462B-BD7B-5F93701760B2Q36200292-808F5E3B-37B5-4CFB-8A62-F05B5BE60CB5Q36290416-B332DE6A-C4F6-4EE9-9B5D-3CBAB60BAF6AQ36317352-1DFB3E3B-5567-4E7F-83F2-9D6A46ACB05CQ36729900-C8BAE52C-8B9B-4131-9A4E-72DFBF25D6C8Q36935025-EFF29CF4-2512-4EB8-8064-CE5197F4A10FQ37358632-45FAC736-AA00-471A-A02F-B056B6D4F995Q37663921-EE9FFCD2-CEEB-4E90-BF41-A3BB6B49A474Q38074112-C0C3B7A1-33E8-4CC0-96A1-CD44057A1C58Q38946139-C17182FE-E42F-4486-83F8-FE851032FB97Q40232892-0314946B-A6BD-423F-A113-470DD03EE6EFQ40302226-192916E3-CB37-4661-9F16-3871DD611BDFQ40548267-0D1B7B7D-D09D-4B2B-9603-4B3812980E9DQ40690097-6B113D38-495A-4A08-85C7-9985B464D90CQ41482932-4D813575-69D4-4696-A6F0-160B7F838885Q41682696-EE0B98DF-016B-4E5F-A42D-502388D54E12Q42202640-1FCD2956-E45E-4B4E-B41E-B884DD41860BQ42219509-8B1AEE8A-9BC8-4FDA-AAF7-2AC1CADFEE12Q42243719-A042DFBD-63F3-490D-AAF0-07BDB252AF6AQ42263146-B4AAEA90-FEFE-4056-A233-C1343009E447Q42271736-703555E2-BE68-4537-BFC1-F78478AEFC4CQ42983977-921AAC68-8390-477A-A03F-085C9438F47FQ42988052-3B3599EC-AED6-4A23-B9F1-C2535D34A454Q43452308-24080443-4505-4A6E-BD3C-633B9A58C8DFQ46661989-13C53EC0-FE44-468D-BE84-A7EEE98180BA
P2860
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
@ast
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
@en
type
label
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
@ast
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
@en
prefLabel
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
@ast
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
@en
P1476
A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
@en
P2093
Elena Vezali
Massimo Colombo
P304
P356
10.1016/S0149-2918(11)00022-1
P577
2010-12-01T00:00:00Z